Yun Zhong
Stock Analyst at Wedbush
(2.31)
# 2,684
Out of 5,005 analysts
37
Total ratings
54.55%
Success rate
-3.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $8.43 | +113.52% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $7.95 | +403.14% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $7.29 | +284.09% | 1 | Aug 11, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $212 → $220 | $204.05 | +7.82% | 2 | Aug 8, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $4.86 | +64.61% | 2 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $18 | $7.15 | +151.75% | 1 | Jun 23, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $15.94 | -5.90% | 2 | May 30, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $3.03 | +164.03% | 1 | May 27, 2025 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Outperform | $32 | $3.15 | +915.87% | 2 | May 16, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $64.83 | +7.97% | 2 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $9.10 | +31.87% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $9.96 | +181.12% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.76 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $8.20 | +95.12% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $22.64 | +606.71% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $54.92 | -16.24% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.04 | +390.20% | 1 | May 5, 2021 |
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $8.43
Upside: +113.52%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $7.95
Upside: +403.14%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $7.29
Upside: +284.09%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $212 → $220
Current: $204.05
Upside: +7.82%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.86
Upside: +64.61%
Wave Life Sciences
Jun 23, 2025
Reiterates: Outperform
Price Target: $18
Current: $7.15
Upside: +151.75%
Keros Therapeutics
May 30, 2025
Reiterates: Neutral
Price Target: $15
Current: $15.94
Upside: -5.90%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $3.03
Upside: +164.03%
Rocket Pharmaceuticals
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.15
Upside: +915.87%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $64.83
Upside: +7.97%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $9.10
Upside: +31.87%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $9.96
Upside: +181.12%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.76
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $8.20
Upside: +95.12%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $22.64
Upside: +606.71%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $54.92
Upside: -16.24%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.04
Upside: +390.20%